|Paris, France, April 26, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported its cash position as of March 31, 2017.
Cash and cash equivalents
GenSight Biologics’ cash and cash equivalents amounted to €48.8 million as of March 31, 2017, compared to €54.0 million as of December 31, 2016.
Number of outstanding shares
As of March 31, 2017, GenSight Biologics’ number of outstanding shares was 19,540,453 ordinary shares.
GenSight Biologics will report its financial statements and update for the first half of 2017 on July 28, 2017.
Please find the full PDF press release attached.gensight_biologics___pr___20170426